Oxford to study anti-inflammatory drug Humira as potential COVID-19 treatment



a close up of a fish: FILE PHOTO: A computer image created by Nexu Science Communication together with Trinity College in Dublin, shows a model structurally representative of a betacoronavirus which is the type of virus linked to COVID-19


© Reuters/Social Media
FILE PHOTO: A computer image created by Nexu Science Communication together with Trinity College in Dublin, shows a model structurally representative of a betacoronavirus which is the type of virus linked to COVID-19

By Josephine Mason and Kate Kelland

LONDON (Reuters) – Oxford University said on Wednesday it would study whether the world’s best-selling prescription medicine, adalimumab, was an effective treatment for COVID-19 patients – the latest effort to repurpose existing drugs as potential coronavirus therapies.

Adalimumab, which is sold under the brand name Humira by AbbVie, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Recent studies have shown that COVID-19 patients already taking anti-TNF drugs for inflammatory bowel disease and inflammatory arthritis are less likely to be admitted to hospital, Oxford said in a statement.



a screen shot of a computer: FILE PHOTO: The coronavirus disease (COVID-19) outbreak in Oldham


© Reuters/PHIL NOBLE
FILE PHOTO: The coronavirus disease (COVID-19) outbreak in Oldham

Oxford’s trial, called AVID-CC,

Read More